Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease) – Drugs In Development, 2024
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease) – Drugs In Development, 2024 report and make more profitable business decisions.
Giant cell arteritis (GCA) is a form of vasculitis, a group of disorders that cause inflammation of blood vessels that affects the arteries of the head (especially the temporal arteries, located on each side of the head). It is also called as temporal arteritis (TA) or cranial arteritis or Horton’s syndrome.
The Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease) drugs in development market research report provide comprehensive information on the therapeutics under development for Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- Therapeutics in Development: Covering 7 molecules, with 7 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncCelon Pharma SA
Eli Lilly and Co
Fresenius Kabi SwissBioSim GmbH
Johnson & Johnson
JSR Life Sciences LLC
Kiniksa Pharmaceuticals Ltd
Novartis AG